[Clinical Characteristics and Prognosis of Systemic Anaplastic Large Cell Lymphoma]

To evaluate the clinical characteristics, treatment and prognosis of systemic anaplastic large cell lymphoma(sALCL).The clinical data of 90 cases with sALCL treated in the Department of Hematology of the Affiliated Xijing Hospital of Air Force Medical University from November 2018 to October 2021 were retrospectively analyzed. The clinical features, treatment and prognosis were summarized and the prognostic factors were investigated.There were 58 males and 32 females, with a median age of 32 (12-73) years old. 69 (76.7%) patients had Ann Arbor stage Ⅲ-Ⅳ disease and half of the patients had extranodal infiltration. The median age was 27(12-72) years of the 60 ALKsALCL mainly occurs in males and most patients were in advanced stage. Half of the patients had extranodal involvement. The CR rate after first-line chemotherapy was 568%, and IPI score≥3 was a significant prognostic factor for CR. No achievement of CR after first-line therapy is poorly prognostic for PFS and OS.系统性间变大细胞淋巴瘤患者的临床特点及预后分析.评价系统性间变大细胞淋巴瘤（sALCL）患者的临床特征、治疗及预后.回顾性分析2018年11月至2021年10月空军军医大学西京医院血液内科收治的90例sALCL患者的临床资料，总结其临床特点、治疗及预后，并探讨预后影响因素.90例sALCL患者中男性58例，女性32例，中位年龄32（12－73）岁。69例（76.7%）患者发病时Ann Arbor 分期为Ⅲ－Ⅳ期，半数患者有结外病变。ALKsALCL以男性居多，诊断时多处于进展期，50%患者合并结外病变。一线化疗后CR率为56.8%，IPI≥3分是一线化疗后CR的不良影响因素。一线化疗后未达CR是PFS及OS 的不良预后因素.